Senseonics Holdings, Inc. (SENS)
NYSEAMERICAN: SENS · IEX Real-Time Price · USD
0.466
+0.014 (3.10%)
At close: Jul 19, 2024, 4:00 PM
0.470
+0.004 (0.88%)
Pre-market: Jul 22, 2024, 7:07 AM EDT
Company Description
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Senseonics Holdings, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 132 |
| CEO | Dr. Timothy T. Goodnow Ph.D. |
Contact Details
Address: 20451 Seneca Meadows Parkway Germantown, Maryland 20876 United States | |
| Phone | (301) 515-7260 |
| Website | senseonics.com |
Stock Details
| Ticker Symbol | SENS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001616543 |
| CUSIP Number | 81727U105 |
| ISIN Number | US81727U1051 |
| Employer ID | 47-1210911 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy T. Goodnow Ph.D. | President, Chief Executive Officer and Director |
| Dr. Mukul Jain | Chief Operating Officer |
| Kenneth L. Horton | General Counsel and Corporate Development Advisor |
| Dr. Francine Ratner Kaufman M.D. | Chief Medical Officer and Director |
| Frederick T. Sullivan | Chief Financial Officer, Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | 8-K | Current Report |
| May 31, 2024 | SD | Form - SD |
| May 22, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 12, 2024 | ARS | Filing |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 25, 2024 | 8-K | Current Report |